SCHEMBL763259

SCHEMBL763259

C=Cc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.60
CYP1A2 P05177 1/20 0.60
PTGS1 P23219 1/20 0.60
SLC6A2 P23975 1/20 0.60
CYP2C19 P33261 1/20 0.60
PTGS2 P35354 1/20 0.60
SLC6A3 Q01959 1/20 0.60
HIF1A Q16665 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
LCK P06239 1/20 0.58
MAOB P27338 3/20 0.58
GAA P10253 2/20 0.58
MAPT P10636 2/20 0.58
L3MBTL1 Q9Y468 2/20 0.58
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
MAOA P21397 1/20 0.58
GSK3B P49841 2/20 0.57
BACE1 P56817 2/20 0.57
BCHE P06276 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480744 0.95 LMNA (0.55) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL2516876 0.92 APP (0.58) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6388039 0.90 APP (0.54) LCKMAOBRAB9ASMN1; SMN2BCHE
SCHEMBL13242652 0.90 APP (0.54) LCKMAOBRAB9ASMN1; SMN2BCHE
SCHEMBL12459750 0.90 GSTP1 (0.58) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL21244014 0.87 TSHR (0.47) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL261149 0.85 MEN1 (0.50) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL14732711 0.85 LCK (0.46) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL6584011 0.85 LMNA (0.56) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL31453872 0.85 APP (0.48) LCKRAB9ASMN1; SMN2ALDH1A1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3532898-B1 METHOD FOR PRODUCING A POLYMER BY NITROXYL-CONTROLLED POLYMERISATION, AND POLYMER FRAUNHOFER GES FORSCHUNG (DE) 2024-07-31 EP claimed
US-11292859-B2 Method for producing a polymer by nitroxyl-controlled polymerisation, and polymer FRAUNHOFER-GESELLSCHAFT ZURFÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2022-04-05 US claimed
CN-113061203-B Catalyst and preparation method thereof, and preparation method of styrene monomer isotactic polymer 中国科学院长春应用化学研究所 2022-03-29 CN claimed
CN-113061203-A Catalyst and preparation method thereof, and preparation method of styrene monomer isotactic polymer 中国科学院长春应用化学研究所 2021-07-02 CN claimed
US-20190248927-A1 METHOD FOR PRODUCING A POLYMER BY NITROXYL-CONTROLLED POLYMERISATION, AND POLYMER Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) 2019-08-15 US claimed
CN-103709030-A Environmentally-friendly preparation method of ciprofibrate ANHUI ANTENG PHARMACEUTICAL CO LTD 2014-04-09 CN claimed
US-7141355-B2 Radiation-sensitive resin composition JSR CORPORATION (JP) 2006-11-28 US claimed
EP-1257265-B1 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS BIOAGENCY AG (DE) 2004-01-21 EP claimed
US-20030036532-A1 Use of 2-phenylene diamine derivatives for the treatment of infections JOMAA PHARMAKA GMBH (DE) 2003-02-20 US claimed
EP-1257265-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS Jomaa Pharmaka GmbH (DE) 2002-11-20 EP claimed
WO-2001070026-A2 2-PHENYLENEDIAMINE DERIVATIVES AS HERBICIDES JOMAA PHARMAKA GMBH (DE) 2001-09-27 WO claimed
WO-2001062709-A2 USE OF 2-PHENYLENE DIAMINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS JOMAA PHARMAKA GMBH (DE) 2001-08-30 WO claimed
EP-1068176-A1 CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS Jomaa, Hassan (DE) 2001-01-17 EP claimed
WO-2000027803-A1 CYSTEINE AMIDES AS FARNESYL TRANSFERASE INHIBITORS JOMAA, HASSAN (DE) 2000-05-18 WO claimed
CN-120025475-A Polymer and deprotection system, method and application 上海微悦芯材新材料有限责任公司 2025-05-23 CN disclosed
WO-2025095132-A1 POROUS RESIN BEAD, METHOD FOR PRODUCING SAME, AND METHOD FOR PRODUCING NUCLEIC ACID USING SAID POROUS RESIN BEAD 日東電工株式会社 2025-05-08 WO disclosed
EP-3532898-B1 METHOD FOR PRODUCING A POLYMER BY NITROXYL-CONTROLLED POLYMERISATION, AND POLYMER FRAUNHOFER GES FORSCHUNG (DE) 2024-07-31 EP disclosed
EP-0304613-B1 BENZOPYRAN DERIVATIVES BASF Aktiengesellschaft (DE) 1991-06-26 EP disclosed
US-4958021-A PRESSURE AND HEAT SENSITIVE RECORDING MATERIALS BASF AKTIENGESELLSCHAFT (DE) 1990-09-18 US disclosed
EP-0304613-A1 Benzopyran derivatives BASF Aktiengesellschaft (DE) 1989-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030036532-A1 Use of 2-phenylene diamine derivatives for the treatment of infections HRH2, ASPH, NQO2 LMNA 3574/4885CYP1A2 91/4885PTGS1 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.